Carl Lee Gilbert

US Patent:

56210396, Apr 15, 1997

Filed:

Jun 8, 1993

Appl. No.:

8/073531

Inventors:

Terrence W. Hallahan - Metuchen NJ
Carl W. Gilbert - Basking Ridge NJ

International Classification:

A61K 3800

US Classification:

525 541

Abstract:

Conjugates containing a substance with coagulant activity, such as recombinant Factor IX, non-antigenic polymers, such as poly(ethylene glycol), are disclosed. Also disclosed are methods of forming the novel conjugates of this invention.

US Patent:

57119449, Jan 27, 1998

Filed:

Nov 10, 1994

Appl. No.:

8/337567

Inventors:

Carl W. Gilbert - Basking Ridge NJ
Myung-Ok Cho - Highland Park NJ

Assignee:

Enzon, Inc. - Piscataway NJ

International Classification:

A61K 3821

US Classification:

424 857

Abstract:

A process is disclosed for preparing long-acting alpha interferon-containing compositions. Alpha interferon is contacted with a relatively small molar excess of a substantially non-antigenic polymer in the presence of a surfactant to preserve bioactivity. Isolation of the desired conjugate species having optimal activity is also disclosed.

US Patent:

59817097, Nov 9, 1999

Filed:

Dec 19, 1997

Appl. No.:

8/994623

Inventors:

Richard B. Greenwald - Somerset NJ
Carl W. Gilbert - Powder Springs GA

Assignee:

Enzon, Inc. - Piscataway NJ

International Classification:

C07K 1113
C07K 1456

US Classification:

530351

Abstract:

A process for preparing. alpha. -interferon-polymer conjugates having high levels of retained interferon activity and relatively long circulating lives in vivo is disclosed. The process includes forming substantially non-antigenic. alpha. -interferon-polymer conjugates, combining the. alpha. -interferon-polymer conjugates with a sufficient amount of an acid to reduce the pH of the conjugates to a level which is sufficient to cleave the polymer linkages in an active site area of the interferon and thereafter adjusting the. alpha. -interferon-polymer conjugates to a physiologically-acceptable pH. Methods of treating interferon-susceptible conditions with the compositions of the present invention are also disclosed.

US Patent:

57388466, Apr 14, 1998

Filed:

Nov 21, 1995

Appl. No.:

8/561616

Inventors:

Richard B. Greenwald - Somerset NJ
Carl W. Gilbert - Basking Ridge NJ

Assignee:

Enzon, Inc. - Piscataway NJ

International Classification:

A61K 3821

US Classification:

424 857

Abstract:

Interferon-polymer conjugate containing compositions having high levels of retained interferon activity and relatively long circulating lives in vivo are disclosed. The compositions contain a mixture of mono-interferon-polymer conjugates and bis-interferon-polymer conjugates, with both species containing substantially a single polymer strand. The conjugate compositions are prepared by reacting about 1 mole of an interferon with from about 0. 125 to about 1 mole of a bis-activated substantially non-antigenic polymer under conditions sufficient to effect covalent conjugation of the interferon and polymer. Methods of treating interferon-susceptible conditions with the compositions of the present invention are also disclosed.

US Patent:

56503881, Jul 22, 1997

Filed:

Jun 30, 1995

Appl. No.:

8/497031

Inventors:

Robert G. L. Shorr - Edison NJ
Carl W. Gilbert - Basking Ridge NJ

Assignee:

Enzon, Inc. - Piscataway NJ

International Classification:

A61K 3842
C07K 1405

US Classification:

514 6

Abstract:

Polyalkylene oxide-conjugated hemoglobin solutions having a molecular weight greater than about 85,000 daltons and a degree of substitution of which substantially avoids clinically significant nephrotoxicity associated with hemoglobinuria in mammals. A method of simultaneously fractionating and purifying polyalkylene oxide-conjugated hemoglobins is al so disclosed.

US Patent:

57051534, Jan 6, 1998

Filed:

Oct 23, 1996

Appl. No.:

8/735961

Inventors:

Robert G. L. Shorr - Edison NJ
Carl W. Gilbert - Basking Ridge NJ
Brian M. Martin - Rockville MD
Myung-Ok Cho - Seoul, KR
Edward J. Ginns - Bethesda MD

Assignee:

The United States of America, as represented by The Department of Health
and Human Services - Washington DC

International Classification:

A61K 3847
C12N 996
C12N 942

US Classification:

424 9461

Abstract:

Conjugates containing glucocerebrosidase and non-antigenic polymers such as polyethylene glycol are disclosed. The conjugates circulate for extended times and have prolonged activity in vivo when compared to unmodified enzymes. The conjugates are useful in the treatment of Gaucher's Disease and have improved enzyme activity at the pH ranges associated with lysosomal, arterial and capillary regions.

US Patent:

59690402, Oct 19, 1999

Filed:

Dec 13, 1996

Appl. No.:

8/766288

Inventors:

Terrence W. Hallahan - Metuchen NJ
Carl W. Gilbert - Basking Ridge NJ

International Classification:

A61K 3800

US Classification:

525 541

Abstract:

Conjugates containing a substance with coagulant activity, such as recombinant Factor IX, non-antigenic polymers, such as poly(ethylene glycol), are disclosed. Also disclosed are methods of forming the novel conjugates of this invention.

US Patent:

56208847, Apr 15, 1997

Filed:

Nov 30, 1994

Appl. No.:

8/346680

Inventors:

Robert G. L. Shorr - Edison NJ
Myung-Ok Cho - Highland Park NJ
Carl W. Gilbert - Basking Ridge NJ
Edward J. Ginns - Bethesda MD
Brian M. Martin - Rockville MD

Assignee:

Enzon, Inc. - Piscataway NJ

International Classification:

C12N 996
C12N 942
A61K 3847

US Classification:

435188

Abstract:

Conjugates containing glucocerebrosidase and non-antigenic polymers such as polyethylene glycol are disclosed. The conjugates circulate for extended times and have prolonged activity in vivo when compared to unmodified enzymes. The conjugates are useful in the treatment of Gaucher's Disease and have improved enzyme activity at the pH ranges associated with lysosomal, arterial and capillary regions.